Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2026-08-30
Target enrollment:
Participant gender:
Summary
Multicenter, open-label, dose-escalation, safety, tolerability, PK and pharmacodynamic study
with a dose expansion at the RP2D to evaluate safety and potential antitumor activity of Q901